AU583439B2 - Prodrugs of rapamycin - Google Patents

Prodrugs of rapamycin

Info

Publication number
AU583439B2
AU583439B2 AU66080/86A AU6608086A AU583439B2 AU 583439 B2 AU583439 B2 AU 583439B2 AU 66080/86 A AU66080/86 A AU 66080/86A AU 6608086 A AU6608086 A AU 6608086A AU 583439 B2 AU583439 B2 AU 583439B2
Authority
AU
Australia
Prior art keywords
sub
prodrugs
rapamycin
carbon atoms
formulawherein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU66080/86A
Other languages
English (en)
Other versions
AU6608086A (en
Inventor
Paul Edwin Kennedy
Valentino John Stella
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kansas
Original Assignee
University of Kansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Kansas filed Critical University of Kansas
Publication of AU6608086A publication Critical patent/AU6608086A/en
Application granted granted Critical
Publication of AU583439B2 publication Critical patent/AU583439B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU66080/86A 1985-12-06 1986-12-04 Prodrugs of rapamycin Ceased AU583439B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/806,152 US4650803A (en) 1985-12-06 1985-12-06 Prodrugs of rapamycin
US806152 1985-12-06

Publications (2)

Publication Number Publication Date
AU6608086A AU6608086A (en) 1987-06-11
AU583439B2 true AU583439B2 (en) 1989-04-27

Family

ID=25193443

Family Applications (1)

Application Number Title Priority Date Filing Date
AU66080/86A Ceased AU583439B2 (en) 1985-12-06 1986-12-04 Prodrugs of rapamycin

Country Status (16)

Country Link
US (1) US4650803A (enExample)
EP (1) EP0227355B1 (enExample)
JP (2) JPH0670066B2 (enExample)
KR (2) KR940004072B1 (enExample)
AT (1) ATE74134T1 (enExample)
AU (1) AU583439B2 (enExample)
CA (2) CA1273920A (enExample)
DE (1) DE3684574D1 (enExample)
DK (2) DK169409B1 (enExample)
ES (1) ES2032750T3 (enExample)
GB (1) GB2183647A (enExample)
GR (1) GR3004530T3 (enExample)
HU (1) HU198054B (enExample)
IE (1) IE64506B1 (enExample)
PT (1) PT83843B (enExample)
ZA (1) ZA869181B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU630866B2 (en) * 1987-12-09 1992-11-12 Fisons Plc Macrocyclic compounds

Families Citing this family (221)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2420367A (en) * 1943-11-09 1947-05-13 Celanese Corp Fluffing up artificial staple fibers
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
DK520482A (da) * 1982-11-23 1984-05-24 Jacobsen P E B Sundhedsmadras
DK406686D0 (da) * 1986-08-26 1986-08-26 Hans Bundgaard Carboxylsyrederivater
GB8728820D0 (en) * 1987-12-09 1988-01-27 Fisons Plc Compounds
EP0378318A1 (en) * 1989-01-11 1990-07-18 Merck & Co. Inc. Process for synthesis of FK-506 and tricarbonyl intermediates
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
ATE126803T1 (de) * 1989-11-09 1995-09-15 Sandoz Ag Heteroatome enthaltende tricyclische verbindungen.
US5352671A (en) * 1989-11-09 1994-10-04 Sandoz Ltd. Heteroatoms-containing tricyclic compounds
US5208228A (en) * 1989-11-13 1993-05-04 Merck & Co., Inc. Aminomacrolides and derivatives having immunosuppressive activity
US5120726A (en) * 1991-03-08 1992-06-09 American Home Products Corporation Rapamycin hydrazones
US5023264A (en) * 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
JPH04230389A (ja) * 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
US5023263A (en) * 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
US5023262A (en) * 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
PT98990A (pt) * 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5378696A (en) * 1990-09-19 1995-01-03 American Home Products Corporation Rapamycin esters
US5130307A (en) * 1990-09-28 1992-07-14 American Home Products Corporation Aminoesters of rapamycin
US5358944A (en) * 1990-09-19 1994-10-25 American Home Products Corporation Rapamycin esters for treating transplantation rejection
US5221670A (en) * 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
US5233036A (en) * 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5120842A (en) * 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) * 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5194447A (en) * 1992-02-18 1993-03-16 American Home Products Corporation Sulfonylcarbamates of rapamycin
NO921449L (no) * 1991-04-17 1992-10-19 American Home Prod Karbamater av rapamycin
US5118678A (en) * 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5147877A (en) * 1991-04-18 1992-09-15 Merck & Co. Inc. Semi-synthetic immunosuppressive macrolides
US5091389A (en) * 1991-04-23 1992-02-25 Merck & Co., Inc. Lipophilic macrolide useful as an immunosuppressant
US5138051A (en) * 1991-08-07 1992-08-11 American Home Products Corporation Rapamycin analogs as immunosuppressants and antifungals
US5102876A (en) * 1991-05-07 1992-04-07 American Home Products Corporation Reduction products of rapamycin
US5565560A (en) * 1991-05-13 1996-10-15 Merck & Co., Inc. O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5162334A (en) * 1991-05-13 1992-11-10 Merck & Co., Inc. Amino O-alkyl, O-alkenyl and O-alkynlmacrolides having immunosuppressive activity
US5776943A (en) * 1991-05-14 1998-07-07 American Home Products Corporation Rapamycin metabolites
US5118677A (en) * 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
EP0516347A1 (en) * 1991-05-29 1992-12-02 American Home Products Corporation Rapamycin derivatives
WO1992021341A1 (en) * 1991-05-31 1992-12-10 Pfizer Inc. Use of rapamycin prodrugs as immunosuppressant agents
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5189042A (en) * 1991-08-22 1993-02-23 Merck & Co. Inc. Fluoromacrolides having immunosuppressive activity
US5208241A (en) * 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
US5162333A (en) * 1991-09-11 1992-11-10 American Home Products Corporation Aminodiesters of rapamycin
US5151413A (en) * 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
US5164399A (en) * 1991-11-18 1992-11-17 American Home Products Corporation Rapamycin pyrazoles
US5262424A (en) * 1992-02-18 1993-11-16 American Home Products Corporation Composition of sulfonylcarbamates of rapamycin and method of treating diseases requiring immunosuppression therewith
MX9301188A (es) * 1992-03-05 1994-07-29 American Home Prod Nuevos sulfonatos y 42-(n-carboalcoxi)sulfamatos en posicion 42 de la rapamicina, procedimiento para su preparacion y composicion farmaceutica que los comprende.
JP2741285B2 (ja) * 1992-05-22 1998-04-15 千寿製薬株式会社 緑内障治療剤
ZA935111B (en) * 1992-07-17 1994-02-04 Smithkline Beecham Corp Rapamycin derivatives
US5256790A (en) * 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
CA2106034A1 (en) * 1992-09-24 1994-03-25 Ralph J. Russo 21-norrapamycin
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5489680A (en) * 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5480988A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
ES2258763T3 (es) * 1992-10-13 2006-09-01 Wyeth Carbamatos de rapamicina.
US5434260A (en) * 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5262423A (en) * 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5258389A (en) * 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5260300A (en) * 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5349060A (en) * 1993-01-07 1994-09-20 American Home Products Corporation Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents
US5252579A (en) * 1993-02-16 1993-10-12 American Home Products Corporation Macrocyclic immunomodulators
US5310901A (en) * 1993-03-05 1994-05-10 Merck & Co., Inc. O-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynlheteroarylrapamycin derivatives
US5310903A (en) * 1993-03-05 1994-05-10 Merck & Co., Inc. Imidazolidyl rapamycin derivatives
GB9307491D0 (en) 1993-04-08 1993-06-02 Sandoz Ltd Organic compounds
USRE40596E1 (en) * 1993-04-08 2008-12-02 Novartis Ag Rapamycin assay
US5504091A (en) * 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
US7279561B1 (en) 1993-04-23 2007-10-09 Wyeth Anti-rapamycin monoclonal antibodies
JPH08509499A (ja) 1993-04-23 1996-10-08 アボツト・ラボラトリーズ ラパマイシン結合体及び抗体
USRE37421E1 (en) 1993-07-16 2001-10-23 Smithkline Beecham Corporation Rapamycin derivatives
US5387680A (en) * 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
US5391730A (en) * 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5378836A (en) * 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5373014A (en) * 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
US5385909A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5385908A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5385910A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
US5389639A (en) * 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5362735A (en) * 1994-02-23 1994-11-08 Smithkline Beecham Corporation Rapamycin derivatives
US5525610A (en) * 1994-03-31 1996-06-11 American Home Products Corporation 42-Epi-rapamycin and pharmaceutical compositions thereof
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5463048A (en) * 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5693648A (en) * 1994-09-30 1997-12-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having immunosuppressive activity
US5491231A (en) * 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US5922730A (en) * 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
US20060198867A1 (en) * 1997-09-25 2006-09-07 Abbott Laboratories, Inc. Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy
US7399480B2 (en) * 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US6015815A (en) 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
US20030129215A1 (en) * 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
US6890546B2 (en) * 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US7378105B2 (en) * 1997-09-26 2008-05-27 Abbott Laboratories Drug delivery systems, kits, and methods for administering zotarolimus and paclitaxel to blood vessel lumens
US7357942B2 (en) * 1997-09-26 2008-04-15 Abbott Laboratories Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens
US8394398B2 (en) * 1997-09-26 2013-03-12 Abbott Laboratories Methods of administering rapamycin analogs with anti-inflammatories using medical devices
US8057816B2 (en) * 1997-09-26 2011-11-15 Abbott Laboratories Compositions and methods of administering paclitaxel with other drugs using medical devices
US8257726B2 (en) * 1997-09-26 2012-09-04 Abbott Laboratories Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices
US8257725B2 (en) * 1997-09-26 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
US7455853B2 (en) * 1998-09-24 2008-11-25 Abbott Cardiovascular Systems Inc. Medical devices containing rapamycin analogs
US7960405B2 (en) * 1998-09-24 2011-06-14 Abbott Laboratories Compounds and methods for treatment and prevention of diseases
US8257724B2 (en) * 1998-09-24 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
US20060240070A1 (en) * 1998-09-24 2006-10-26 Cromack Keith R Delivery of highly lipophilic agents via medical devices
US6331547B1 (en) 1999-08-18 2001-12-18 American Home Products Corporation Water soluble SDZ RAD esters
US6790228B2 (en) 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US20070032853A1 (en) * 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7807211B2 (en) * 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US6277983B1 (en) 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
MXPA03001245A (es) 2000-08-11 2003-05-27 Wyeth Corp Metodo para el tratamiento del carcionma positivo para receptores de estrogeno.
EP1319008B1 (en) 2000-09-19 2008-10-15 Wyeth Water soluble rapamycin esters
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
CA2444894C (en) * 2001-04-26 2013-06-25 Control Delivery Systems, Inc. Sustained release drug delivery system containing codrugs
US20040022853A1 (en) * 2001-04-26 2004-02-05 Control Delivery Systems, Inc. Polymer-based, sustained release drug delivery system
US20040137066A1 (en) * 2001-11-26 2004-07-15 Swaminathan Jayaraman Rationally designed therapeutic intravascular implant coating
US6641611B2 (en) 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant
US20080145402A1 (en) * 2001-09-10 2008-06-19 Abbott Cardiovascular Systems Inc. Medical Devices Containing Rapamycin Analogs
IN2014DN10834A (enExample) * 2001-09-17 2015-09-04 Psivida Inc
US6939376B2 (en) * 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US7682387B2 (en) 2002-04-24 2010-03-23 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US20040024450A1 (en) * 2002-04-24 2004-02-05 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
AR040693A1 (es) 2002-07-30 2005-04-13 Wyeth Corp Formulaciones parenterales
US20060171984A1 (en) 2002-09-06 2006-08-03 Cromack Keith R Device having hydration inhibitor
DK1592457T3 (da) * 2003-01-27 2012-10-22 Endocyte Inc Folat-vinblastin-konjugat som lægemiddel
US7160867B2 (en) * 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
JP2007510621A (ja) * 2003-07-29 2007-04-26 シグニチャー アールアンドディー ホールディングス，エルエルシー． アミノ酸プロドラッグ
US8173840B2 (en) * 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
US7589233B2 (en) * 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
AU2004274026A1 (en) * 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
US7220755B2 (en) 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
US20100030183A1 (en) * 2004-03-19 2010-02-04 Toner John L Method of treating vascular disease at a bifurcated vessel using a coated balloon
US20070027523A1 (en) * 2004-03-19 2007-02-01 Toner John L Method of treating vascular disease at a bifurcated vessel using coated balloon
US8431145B2 (en) 2004-03-19 2013-04-30 Abbott Laboratories Multiple drug delivery from a balloon and a prosthesis
AU2005222719B2 (en) * 2004-03-19 2011-03-24 Abbott Laboratories Multiple drug delivery from a balloon and a prosthesis
WO2005105811A1 (en) 2004-04-14 2005-11-10 Wyeth Regiospecific synthesis of rapamycin 42-ester derivatives
AU2005238432A1 (en) * 2004-04-14 2005-11-10 Wyeth Process for preparing rapamycin 42-esters and FK-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies
EP1740710A1 (en) * 2004-04-27 2007-01-10 Wyeth Labeling of rapamycin using rapamycin-specific methylases
US7534449B2 (en) * 2004-07-01 2009-05-19 Yale University Targeted and high density drug loaded polymeric materials
US8288557B2 (en) 2004-07-23 2012-10-16 Endocyte, Inc. Bivalent linkers and conjugates thereof
US7901451B2 (en) 2004-09-24 2011-03-08 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
EP1804779A1 (en) * 2004-10-28 2007-07-11 Wyeth Use of an mtor inhibitor in treatment of uterine leiomyoma
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
JP2008530127A (ja) 2005-02-09 2008-08-07 マクサイト， インコーポレイテッド 眼の処置のための処方物
GB0503936D0 (en) 2005-02-25 2005-04-06 San Raffaele Centro Fond Method
EP1863816B1 (en) * 2005-03-16 2014-06-25 Endocyte, Inc. Synthesis and purification of pteroic acid and conjugates thereof
EP1868663B1 (en) * 2005-03-23 2011-11-16 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
WO2007032777A2 (en) 2005-03-23 2007-03-22 Abbott Laboratories Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy
WO2007014278A2 (en) 2005-07-25 2007-02-01 Trubion Pharmaceuticals, Inc. B-cell reduction using cd37-specific and cd20-specific binding molecules
BRPI0615354A2 (pt) * 2005-08-19 2011-05-17 Endocyte Inc conjugado de liberação de fármaco de ligação de receptor, composição farmacêutica que o compreende, bem como seu uso
WO2007056118A1 (en) 2005-11-04 2007-05-18 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
US20070225217A1 (en) 2005-11-09 2007-09-27 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
CA2632239A1 (en) * 2005-12-20 2007-07-05 Wyeth Control of cci-779 dosage form stability through control of drug substance impurities
WO2007092620A2 (en) 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
US20070203169A1 (en) * 2006-02-28 2007-08-30 Zhao Jonathon Z Isomers and 42-epimers of rapamycin ester analogs, methods of making and using the same
US7678901B2 (en) 2006-02-28 2010-03-16 Wyeth Rapamycin analogs containing an antioxidant moiety
US7622477B2 (en) * 2006-02-28 2009-11-24 Cordis Corporation Isomers and 42-epimers of rapamycin alkyl ether analogs, methods of making and using the same
AU2007230964B2 (en) * 2006-03-23 2012-07-19 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
US20080051691A1 (en) * 2006-08-28 2008-02-28 Wyeth Implantable shunt or catheter enabling gradual delivery of therapeutic agents
EP2702993B1 (en) 2006-09-13 2017-12-06 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
BRPI0719509A2 (pt) 2006-09-28 2013-12-31 Follica Inc Métodos, kits e composições para geração de novos folículos pilosos e crescimento de cabelos
US8067055B2 (en) * 2006-10-20 2011-11-29 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method of use
US20080097591A1 (en) 2006-10-20 2008-04-24 Biosensors International Group Drug-delivery endovascular stent and method of use
US20080103584A1 (en) * 2006-10-25 2008-05-01 Biosensors International Group Temporal Intraluminal Stent, Methods of Making and Using
US10265407B2 (en) 2007-02-15 2019-04-23 Yale University Modular nanodevices for smart adaptable vaccines
WO2008101231A2 (en) 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
WO2008109347A2 (en) * 2007-03-02 2008-09-12 Yale University Methods for ex vivo administration of drugs to grafts using polymeric nanoparticles
CN104127878A (zh) 2007-03-14 2014-11-05 恩多塞特公司 结合配体连接的微管溶素递药缀合物
TW200901989A (en) 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
CN104383553A (zh) 2007-06-25 2015-03-04 恩多塞特公司 含有亲水性间隔区接头的共轭物
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
JP2010532764A (ja) * 2007-07-06 2010-10-14 トゥルビオン・ファーマシューティカルズ・インコーポレーテッド Ｃ末端に配置された特異的結合性ドメインを有する結合性ペプチド
US8573150B2 (en) 2007-11-14 2013-11-05 Biosensors International Group, Ltd. Automated stent coating apparatus and method
US20100048913A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
AU2009225434B2 (en) 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
US20090253733A1 (en) * 2008-04-02 2009-10-08 Biointeractions, Ltd. Rapamycin carbonate esters
MX340204B (es) * 2008-04-11 2016-06-30 Emergent Product Dev Seattle Inmunoterapeutico de cd37 y combinacion con quimioterapeutico bifuncional del mismo.
CN102231969A (zh) * 2008-10-03 2011-11-02 万能医药公司 大环内酯化合物及其使用方法
JP2012516900A (ja) 2009-02-05 2012-07-26 トーカイ ファーマシューティカルズ，インク． ステロイド性ｃｙｐ１７阻害剤／抗アンドロゲン剤の新しいプロドラッグ
CN102612564B (zh) 2009-04-10 2015-08-26 齐海燕 新的抗衰老试剂及其鉴别方法
KR20120115237A (ko) 2009-10-30 2012-10-17 어리어드 파마슈티칼스, 인코포레이티드 암 치료 방법 및 조성물
US20110130711A1 (en) * 2009-11-19 2011-06-02 Follica, Inc. Hair growth treatment
US8480620B2 (en) * 2009-12-11 2013-07-09 Abbott Cardiovascular Systems Inc. Coatings with tunable solubility profile for drug-coated balloon
US20110144577A1 (en) * 2009-12-11 2011-06-16 John Stankus Hydrophilic coatings with tunable composition for drug coated balloon
US8951595B2 (en) * 2009-12-11 2015-02-10 Abbott Cardiovascular Systems Inc. Coatings with tunable molecular architecture for drug-coated balloon
WO2011109833A2 (en) 2010-03-05 2011-09-09 President And Fellows Of Harvard College Induced dendritic cell compositions and uses thereof
EP2532740A1 (en) 2011-06-11 2012-12-12 Michael Schmück Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
EP2841098A4 (en) 2012-04-23 2016-03-02 Allertein Therapeutics Llc NANOPARTICLES FOR THE TREATMENT OF ALLERGIES
CN104203959B (zh) 2012-06-08 2017-09-15 百多力股份公司 雷帕霉素40‑o‑环状烃酯、组合物和方法
HK1212618A1 (zh) 2012-10-16 2016-06-17 恩多塞特公司 含有非天然氨基酸的藥物遞送綴合物以及其使用方法
WO2014068070A1 (en) 2012-10-31 2014-05-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
CN105682662A (zh) 2013-03-14 2016-06-15 马里兰大学巴尔的摩校区 雄激素受体减量调节剂及其用途
AU2014248090B2 (en) 2013-04-03 2018-08-02 N-Fold Llc Novel nanoparticle compositions
KR20160058774A (ko) 2013-08-12 2016-05-25 토카이 파마슈티컬, 아이엔씨. 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
CN105461738B (zh) 2014-06-03 2019-03-08 中国人民解放军军事医学科学院毒物药物研究所 一种雷帕霉素衍生物、其制备方法、其药物组合物及用途
EP3193902A4 (en) 2014-09-11 2018-03-28 The Regents of The University of California mTORC1 INHIBITORS
WO2017029391A1 (en) 2015-08-20 2017-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating cancer
US20210177770A1 (en) 2016-04-14 2021-06-17 Spinnaker Biosciences, Inc. Porous silicon materials comprising a metal silicate for delivery of therapeutic agents
WO2019002168A1 (en) 2017-06-26 2019-01-03 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING OLMSTED SYNDROME
EP3652306A1 (en) 2017-07-13 2020-05-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for increasing expansion and immunosuppressive capacity of a population of cd8+cd45rclow/-tregs
AR112834A1 (es) 2017-09-26 2019-12-18 Novartis Ag Derivados de rapamicina
FI3788049T3 (fi) 2018-05-01 2023-05-30 Revolution Medicines Inc C40-, c28- ja c-32-liittyneitä rapamysiinianalogeja mtor-estäjinä
IL278335B2 (en) 2018-05-01 2024-09-01 Revolution Medicines Inc C26-linked rapamycin analogs as mtor inhibitors
AU2019310040A1 (en) 2018-07-23 2021-02-11 Enclear Therapies, Inc. Methods of treating neurological disorders
CN113164563A (zh) 2018-07-23 2021-07-23 因柯利尔疗法公司 神经性病症的治疗方法
US20220047567A1 (en) 2018-09-10 2022-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of neurofibromatosis
WO2020128861A1 (en) 2018-12-18 2020-06-25 Novartis Ag Rapamycin derivatives
CN114007665B (zh) 2019-04-11 2024-11-12 因柯利尔疗法公司 改善脑脊液的方法及其装置和系统
CA3197180A1 (en) 2020-09-29 2022-04-07 Enclear Therapies, Inc. Subarachnoid fluid management method and system
CA3256390A1 (en) 2022-05-25 2023-11-30 Revolution Medicines Inc CANCER TREATMENT METHODS USING AN MTOR INHIBITOR
EP4551219A1 (en) 2022-07-06 2025-05-14 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of proliferative glomerulonephritis
WO2024028433A1 (en) 2022-08-04 2024-02-08 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of lymphoproliferative disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE877700A (fr) * 1978-11-03 1980-01-14 Ayerst Mckenna & Harrison Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
AU543727B2 (en) * 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
US4316885A (en) * 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU630866B2 (en) * 1987-12-09 1992-11-12 Fisons Plc Macrocyclic compounds

Also Published As

Publication number Publication date
DK169409B1 (da) 1994-10-24
DK34793A (da) 1993-03-25
EP0227355A3 (en) 1988-10-12
DK170750B1 (da) 1996-01-08
US4650803A (en) 1987-03-17
CA1273920A (en) 1990-09-11
PT83843B (pt) 1989-01-17
EP0227355A2 (en) 1987-07-01
GB2183647A (en) 1987-06-10
KR940004072B1 (ko) 1994-05-11
CA1312076C (en) 1992-12-29
IE64506B1 (en) 1995-08-09
GB8628994D0 (en) 1987-01-14
JPH0670066B2 (ja) 1994-09-07
GB2183647B (enExample) 1989-10-18
AU6608086A (en) 1987-06-11
JPS62215592A (ja) 1987-09-22
GR3004530T3 (enExample) 1993-04-28
ATE74134T1 (de) 1992-04-15
JPH0747593B2 (ja) 1995-05-24
DK34793D0 (da) 1993-03-25
HU198054B (en) 1989-07-28
ZA869181B (en) 1988-07-27
JPH06263765A (ja) 1994-09-20
KR940004073B1 (ko) 1994-05-11
EP0227355B1 (en) 1992-03-25
PT83843A (en) 1987-01-01
DK584886D0 (da) 1986-12-05
DK584886A (da) 1987-06-07
ES2032750T3 (es) 1993-03-01
DE3684574D1 (de) 1992-04-30
IE863198L (en) 1987-06-06
KR870006072A (ko) 1987-07-09

Similar Documents

Publication Publication Date Title
AU583439B2 (en) Prodrugs of rapamycin
MX9202849A (es) Analogos del agente antitumoral rebecamicina.
DE68917357D1 (de) Derivate der Coffeinsäure und pharmazeutische Zusammensetzungen, die sie enthalten.
NZ230503A (en) Substituted beta-diketones and pharmaceutical compositions
DE3372095D1 (en) Novel phenylpiperazine derivatives and process for producing the same
ES8607265A1 (es) Un procedimiento para la preparacion de nuevos derivados de aminoalcoholes
AU526978B2 (en) Tetracyclic indole derivatives
HUT60261A (en) Process for producing piperazine derivatives and pharmaceutical compositions comprising same
DE3373302D1 (en) Derivatives of aminopyridinecarboxylic acids, methods for their preparation and pharmaceutical compositions containing them
ES459705A1 (es) Procedimiento para la preparacion de derivados de hidracina-piridacina.
FR2694557B1 (fr) Dérivés de tétrahydronaphtalène, leur préparation, et leur application en thérapeutique.
HUT53093A (en) Process for producing substituted 3-amino-sidnonimine derivatives and pharmaceutical compositions them as active components
MY104099A (en) Anti inflammatory carbinoloimidazoles.
ES467409A1 (es) Procedimiento de preparacion de derivados de la ajmalicina.
GB1546702A (en) Benzofuranone derivative